BEDFORD, Ohio — The FDA has announced final approval for Xellia Pharmaceuticals, with a facility in Bedford, Ohio, to begin manufacturing in the coming months critically-needed anti-infective drugs.

The Bedford facility will produce Vancomycin, the gold standard of treatment against bacterial "superbugs" like MRSA, streptococci and c.difficile. Vancomycin can be thought of as a “super” antibiotic. When taken by mouth, Vancomycin fights bacteria in the intestines.

The site will significantly expand Xellia's ability to meet the nationwide and global need for Vancomycin against potential supply-chain disruption caused by the current COVID-19 crisis. Though Vancomycin is not a treatment for COVID-19, it will increase the supply of Vancomycin locally and nationally. Having a regional base for Vancomycin will elevate our current shipping or supply issues.

Xellia Pharmaceuticals has hired 220 employees locally over the past 5 years with 60 positions still in need of filling in Bedford.

Xellia acquired the old Hikma/Ben Venue plant in Bedford five years ago and has invested $200 million to modernize the plant into a state-of-the-art pharmaceutical production facility.

Click here for our special coronavirus section.

RELATED: Could we soon be home-testing for COVID-19?

RELATED: FDA will let doctors treat critically ill patients with blood from coronavirus survivors

RELATED: VERIFY: What are plasma treatments for COVID-19?

RELATED: Cleveland biotech company making headway on possible COVID-19 treatment

RELATED: FDA approves coronavirus test that produces results in 45 minutes